Specifically, KFX significantly reduced the odds of grade 3–4 mucositis (OR = 0.118, 95% CI 0.029–0.488, p = 0.003) (Table 3) and infection (Table 4) (OR = 0.115, 95% CI 0.030–0.439, p = 0.002) after adjusting for age, CD34+ dose, disease stage, and other clinical variables. Here, CD34 is linked to mucositis.